Poor
Partially Aligned
Patient Risk:
Low
Summary
The claims focus mainly on legal/dispensing practices and regulation, which are not addressed in the provided FDA prescribing information excerpts. While a few medication-safety concepts (e.g., urinary retention contraindication) overlap with the label, most statements are not supported or contradicted by the supplied labeling text.
Category Scores
Accurate Statements
Detrol has contraindications.
SECTION 4 — “DETROL Tablets are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma...”
Detrol can worsen certain urinary retention problems.
SECTION 4 — contraindicated in patients with urinary retention; SECTION 5/Precautions — “should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention...”
Unsupported Statements
In most places, Detrol (tolterodine) cannot legally be bought without a prescription.
Not addressed in the provided FDA prescribing information excerpts (Sections 1,2,4,5,6,7,8,12,14).
Detrol (tolterodine) is a prescription-only medication.
Not addressed in the provided FDA prescribing information excerpts.
Pharmacies typically require a valid prescription to dispense Detrol (tolterodine).
Not addressed in the provided FDA prescribing information excerpts.
Detrol is regulated as a prescription drug because it can cause side effects.
The provided label excerpts do not state regulatory rationale tied to side effects.
Detrol can worsen other conditions.
Vague and not tied to specific label-supported conditions/excerpts in the provided text.
Because of safety concerns, pharmacies must verify prescriber authorization before selling Detrol.
Regulatory/dispensing process not addressed in provided FDA prescribing information.
Rules vary by country and by local pharmacy practice.
Not addressed in the provided FDA prescribing information excerpts.
The common rule is still prescription-only.
Not addressed in the provided FDA prescribing information excerpts.
Legitimate pharmacies usually ask for a prescription when selling Detrol.
Not addressed in the provided FDA prescribing information excerpts.
Selling prescription drugs without a prescription is often illegal or unsafe.
General legal/safety assertions not addressed in the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
No mention of label-defined safety topics actually present in the provided excerpts (e.g., anaphylaxis/angioedema warning, need to discontinue for breathing difficulty/airway obstruction/hypotension, QT-related precaution context, guidance on monitoring for anticholinergic CNS effects, and specific contraindications including gastric retention and uncontrolled narrow-angle glaucoma).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only medication-specific safety alignment is partial (urinary retention/contraindication concept). However, most statements are about legal dispensing practices and are not label-supported; there is no direct incorrect dosing or direct contraindication misstatement supported by the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims concern prescription/dispensing legality and pharmacy verification requirements, which are not covered by the provided FDA label excerpts. Medication-specific content is limited and only partially aligns (urinary retention/contraindications).
Suggested Improvement
Restrict claims to label-supported medication facts (e.g., list contraindications from SECTION 4; cite urinary retention/gastric retention caution and anaphylaxis/angioedema warning from SECTION 5; avoid statements about legal purchase requirements or pharmacy dispensing processes unless supported by the label text provided).